Categories
Change Password!
Reset Password!
To completely understand the emerging spectrum of neurological ailments in COVID-19 patients via a weekly virtual COVID-19 neurology multi-disciplinary conference.
Keeping in view the detailed description of
neurological disorders in 43 patients wit COVID-19, this retrospective review
found whole
neuraxis (plus cerebral vasculature) to be affected by COVID. Also, none of the autoantibodies observed in acute
disseminated encephalomyelitis were linked with this infectious disease.
To completely understand the emerging spectrum of
neurological ailments in COVID-19 patients via a weekly virtual COVID-19
neurology multi-disciplinary conference.
In early March 2020, this conference was held to discuss and
begin to apprehend neurological presentations in COVID-19 patients assumed to
have neurological ailments. Detailed clinical and paraclinical data were
gathered from patients where the diagnosis of COVID-19 was confirmed through
RNA Polymerase chain reaction (PCR), or where the diagnosis was probable and
possible as per the WHO standards.
Twenty nine patients were COVID-19 PCR positive and definite, 8 probable and 6 possible, out of the total 43 patients included. The main groups emerged has been displayed in the following table:
The whole neuraxis (cerebral vasculature and response to
immunotherapies in few patients) is affected due to the presence of SARS-CoV-2
infection. Of particular interest is the incidence of acute disseminated
encephalomyelitis, mainly with the haemorrhagic change, not linked to COVID-19
severity. Future clinical, neuroradiological, biomarker and neuropathological
studies are important to understand the causal pathobiological mechanisms for
better management of this infection.
BRAIN- A Journal of Neurology
The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings
Ross W Paterson et al.
Comments (0)